Novo submitted 14 million pages
The pharmaceutical industry is facing stricter regulatory requirements when seeking for approval of new drugs, and the amounts being invested in novel medicine are huge. Here are the numbers from Novo Nordisk.
Insulin Novo Semilente, Insulin Novo Lente, and Insulin Novo Ultralente – three products launched by Novo Nordisk during the 1950s, after the Danish company had applied for marketing approval for the products in 1952.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo rival faces massive challenges
For abonnenter
Novo Nordisk silent about the loss of massive contract
For abonnenter
Flagships keep scientists in Denmark
For abonnenter
